Journal of Osteoporosis / 2011 / Article / Tab 1

Clinical Study

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy

Table 1

Baseline characteristics stratified by presence of vertebral fracture.

No vertebral fracture Vertebral fracture
n = 56n = 22
VariableMedianMeanSDRangeMedianMeanSDRangeP value*

Duration of ADT (months)16.539.644.70.0–10.510.530.343.50.0–156.00.21
Age (years)77.076.58.258.0–77.577.578.06.763.0–88.00.53
Weight (kg)83.584.817.154.5–86.786.787.118.054.8–119.80.46
Height (cm)172.7171.76.1152.4–171.4171.4172.57.1157.5–182.90.83
Height loss (cm)5.15.83.00.8–5.85.86.43.61.3–14.00.58
BMI (kg/m2)28.428.54.918.2–28.628.628.75.518.3–40.40.76
25-(OH) Vitamin D (ng/mL)31.130.314.67.0–26.126.127.110.98.0–57.80.42
Serum calcium (mg/dL)9.79.51.30.7–9.69.69.50.57.9–10.60.52
Parathyroid hormone (pg/mL)44.049.528.116.7–37.337.345.928.815.8–135.00.49
Alkaline phosphatase (U/L)80.092.480.649.0–73.073.074.217.047.0–112.00.16
Prostate-specific antigen (PSA) (ng/mL)0.36.215.10.1–0.30.32.86.70.1–30.70.49
Testosterone (ng/mL)0.10.61.30.1–0.20.21.41.70.1–5.90.01

* P values are from the Wilcoxon rank sum test.